

ICD-10-PCS Procedure Codes					
	CODE	DESCRIPTION			
Lead Implantation or Replacement	00H00MZ	Insertion of Neurostimulator Lead into Brain, Open Approach			
	00H03MZ	Insertion of Neurostimulator Lead into Brain, Percutaneous Approach			
	00H04MZ	Insertion of Neurostimulator Lead into Brain, Percutaneous Endoscopic Approach			
Generator Implantation or Replacement	0NH00NZ	Insertion of Neurostimulator Generator into Skull, Open Approach			
Lead Removal	0OP00MZ	Removal of Neurostimulator Lead from Brain, Open Approach			
Generator Removal	0NP00NZ	Removal of Neurostimulator Generator from Skull, Open Approach			
MS-DRG Assignments					
	ICD-10 CODE(S)	MS-DRG	MS-DRG TITLE	MEDICARE RELATIVE WEIGHT	
Implantation of RNS System Leads and Generator	00H00MZ AND 0NH00NZ <i>OR</i> 00H03MZ AND 0NH00NZ <i>OR</i> 00H04MZ AND 0NH00NZ	023	Craniotomy with Major Device Implant or Acute Complex Central Nervous System (CNS) Principal Diagnosis (PDX) with MCC or Chemotherapy Implant or Epilepsy with Neurostimulator	5.7314	
	Replacement of Generator Only or Removal of Generator Only	0NH00NZ	040	Peripheral/Cranial Nerve & Other Nervous System Procedures with MCC	3.7884
		OR 0NP00NZ	041	Peripheral/Cranial Nerve & Other Nervous System Procedures with CC or Peripheral Neurostimulator	2.3381
			042	Peripheral/Cranial Nerve & Other Nervous System Procedures without CC/MCC	1.8497
	Removal of Leads and Generator	0OP00MZ AND 0NP00NZ	025	Craniotomy and Endovascular Intracranial Procedures with MCC	4.5405
		026	Craniotomy and Endovascular Intracranial Procedures with CC	3.0235	
		027	Craniotomy and Endovascular Intracranial Procedures without CC/MCC	2.4954	

ICD-10-CM Diagnosis Codes

CODE	DESCRIPTION
G40.011	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus
G40.019	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus
G40.111	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus
G40.119	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus
G40.211	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus
G40.219	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus

Important Notes

Starting in Fiscal Year (FY) 2018, the Centers for Medicare & Medicaid Services (CMS) reassigned all cases involving implantation of the RNS® System (leads and generator) to MS-DRG 023.

Correct coding is critical for ensuring that the procedure maps to the appropriate MS-DRG. Per the CMS FY 2018 Inpatient Prospective Payment System final rule, cases involving the RNS® System will map to MS-DRG 023 when a principal diagnosis of epilepsy and one of the following ICD-10-PCS procedure code combinations are reported:

- ONH00NZ and 00H00MZ
- ONH00NZ and 00H03MZ
- ONH00NZ and 00H04MZ

About NeuroPace and the RNS® System

NeuroPace develops, manufactures and markets implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's first product, the RNS® System, is the only FDA-approved brain-responsive neurostimulator for the treatment of refractory focal onset epilepsy.

FDA Indication for Use

The RNS® System is an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures (motor partial seizures, complex partial seizures and/or secondarily generalized seizures). The RNS® System has demonstrated safety and effectiveness in patients who average 3 or more disabling seizures per month over the three most recent months (with no month with fewer than two seizures), and has not been evaluated in patients with less frequent seizures.



See labeling available at www.NeuroPace.com for prescribing information, including indications, contraindications, warnings, precautions and adverse events.

This document has been prepared for providers using the RNS® System, and is intended for informational purposes only. NeuroPace does not promise or guarantee coverage or any level of payment by any third party payer. While NeuroPace believes this information to be correct, it is subject to change at any time. As with all reimbursement claims, providers are solely responsible for determining the appropriate codes, modifiers and charges for services provided. NeuroPace recommends that you contact your local payer with questions regarding coding and payment guidelines.

The FY2023 Medicare MS-DRGs and relative weights can be found in the Federal Register, Volume 87, Number 153, August 10, 2022.